Sydney, Oct 5, 2007 AEST (ABN Newswire) - Ventracor (ASX: VCR) today announced the 150th implant of the VentrAssist Left Ventricular Assist Device (LVAD).
Ventracor also reports 11 patients have been enrolled in the US Bridge To Transplant (BTT) Pivotal Trial and four enrolled in the US Destination Therapy (DT) Trial.
Ventracor Chief Executive Officer Peter Crosby said: "We are pleased with the growing momentum as the number of centres has grown from the original four to now 23 centres working through the process of Institutional Review Board (ethics committee) approval, training, and site initiation, which includes eight sites ready to enroll in the BTT trial, and six sites ready to enroll in the DT trial. We anticipate the implant rate will increase in the coming months as more centers become active."
He added there was continued strong interest from hospitals in the US to participate in the trials, and that this weekend, Ventracor's US team will host an investigators' meeting with over 80 clinicians and affiliates participating in the US BTT and DT trials.
Contact
Graeme Fallet
Company Secretary and Chief Financial
Officer or
Andrew Geddes
Manager, Investor Relations
TEL: +61 2 9406 3100
Email info@ventracor.com
www.ventracor.com
| ||
|
